ProBio opened its Cell and Gene Therapy Center of Excellence on June 27, 2025, at the Princeton West Innovation Campus in Hopewell, New Jersey. The 128,000-sq-ft GMP facility manufactures plasmid DNA and viral vectors, including adeno-associated virus (AAV) and lentiviral vector (LVV) platforms, and serves as ProBio’s North American hub. The opening created over 110 high-skilled jobs, according to the company.
What it means
The Hopewell facility adds domestic GMP manufacturing capacity for two cell and gene therapy platform technologies. ProBio said GMP AAV manufacturing is set to launch by Q3 2025, with GMP LVV services to follow in Q1 2026. Hopewell Township Mayor Courtney Peters-Manning said the facility will produce “cutting-edge, life-changing therapies, in addition to creating high-skilled jobs.” CEO Allen Guo said at the grand opening, “This is not just a new facility. It is a beacon of hope for patients waiting for cures.”
Key facts
- Facility size: 128,000 sq ft GMP
- Location: Princeton West Innovation Campus, Hopewell, New Jersey
- Products: plasmid DNA, AAV, and lentiviral vector (LVV) platforms
- Jobs created: over 110 high-skilled positions, according to the company
- GMP AAV manufacturing launch: Q3 2025
- GMP LVV services launch: Q1 2026
- U.S. Site Head: Michael Vreeland
- CEO: Allen Guo
Source: ProBio news release (PR Newswire)